Skip to content
TrialScanner

NCT03828448

Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular Lymphoma

Phase 2TerminatedTGTXLead

Registry record

Lead sponsor
TG Therapeutics, Inc.
Conditions
Follicular Lymphoma; Small Lymphocytic Lymphoma
Primary completion
May 16, 2022Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT03828448 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT03828448: Study to Assess Umbralisib... | TrialScanner